Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology
- Written by ACN Newswire
Paris, France, Cambridge, MA, May 31, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept...
Read more: Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology